Axsome Therapeutics (AXSM) Retained Earnings (2015 - 2026)
Axsome Therapeutics (AXSM) reported Retained Earnings of -$1.4 billion for Q1 2026, down 15.93% on a YoY basis from -$1.6 billion in Q1 2025, and down 4.94% sequentially from -$1.3 billion in Q4 2025.
Axsome Therapeutics (AXSM) Retained Earnings (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of Retained Earnings data on file, last reported at -$1.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 15.93% year-over-year to -$1.4 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.4 billion (down 15.93% YoY), and the FY2025 full-year result was -$1.3 billion, down 16.31% from the prior year.
- Retained Earnings eased to -$1.4 billion in Q1 2026, from -$1.3 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$448.8 million in Q1 2022 to a low of -$1.4 billion in Q1 2026.
- A 5-year average of -$902.9 million and a median of -$903.9 million in 2024 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings tumbled 48.78% in 2024 and slipped 15.93% in 2026, its largest moves.
- Tracing AXSM's Retained Earnings over 5 years: stood at -$596.3 million in 2022, then plunged by 40.12% to -$835.6 million in 2023, then sank by 34.37% to -$1.1 billion in 2024, then retreated by 16.31% to -$1.3 billion in 2025, then fell by 4.94% to -$1.4 billion in 2026.
- Business Quant data shows AXSM's Retained Earnings at -$1.4 billion in Q1 2026, -$1.3 billion in Q4 2025, and -$1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Axsome Therapeutics | 12.37 Bn | 12.06 Bn | 176.48 Mn | -1.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.37 Bn |
| Dec 31, 2025 | -1.31 Bn |
| Sep 30, 2025 | -1.28 Bn |
| Jun 30, 2025 | -1.23 Bn |
| Mar 31, 2025 | -1.18 Bn |
| Dec 31, 2024 | -1.12 Bn |
| Sep 30, 2024 | -1.05 Bn |
| Jun 30, 2024 | -983.27 Mn |
| Mar 31, 2024 | -903.90 Mn |
| Dec 31, 2023 | -835.57 Mn |
| Sep 30, 2023 | -736.92 Mn |
| Jun 30, 2023 | -674.70 Mn |
| Mar 31, 2023 | -607.55 Mn |
| Dec 31, 2022 | -596.33 Mn |
| Sep 30, 2022 | -535.10 Mn |
| Jun 30, 2022 | -490.27 Mn |
| Mar 31, 2022 | -448.83 Mn |
| Dec 31, 2021 | -409.20 Mn |
| Sep 30, 2021 | -375.20 Mn |
| Jun 30, 2021 | -340.30 Mn |